CA2436196A1 - Virus oncolytique pour eliminer les cellules de tumeurs malignes lymphoides presentes dans des melanges de cellules - Google Patents

Virus oncolytique pour eliminer les cellules de tumeurs malignes lymphoides presentes dans des melanges de cellules Download PDF

Info

Publication number
CA2436196A1
CA2436196A1 CA002436196A CA2436196A CA2436196A1 CA 2436196 A1 CA2436196 A1 CA 2436196A1 CA 002436196 A CA002436196 A CA 002436196A CA 2436196 A CA2436196 A CA 2436196A CA 2436196 A1 CA2436196 A1 CA 2436196A1
Authority
CA
Canada
Prior art keywords
cells
virus
reovirus
cellular composition
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002436196A
Other languages
English (en)
Inventor
Unknown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Priority to CA002436196A priority Critical patent/CA2436196A1/fr
Publication of CA2436196A1 publication Critical patent/CA2436196A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002436196A 2003-07-25 2003-07-25 Virus oncolytique pour eliminer les cellules de tumeurs malignes lymphoides presentes dans des melanges de cellules Abandoned CA2436196A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002436196A CA2436196A1 (fr) 2003-07-25 2003-07-25 Virus oncolytique pour eliminer les cellules de tumeurs malignes lymphoides presentes dans des melanges de cellules

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002436196A CA2436196A1 (fr) 2003-07-25 2003-07-25 Virus oncolytique pour eliminer les cellules de tumeurs malignes lymphoides presentes dans des melanges de cellules

Publications (1)

Publication Number Publication Date
CA2436196A1 true CA2436196A1 (fr) 2005-01-25

Family

ID=34085282

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002436196A Abandoned CA2436196A1 (fr) 2003-07-25 2003-07-25 Virus oncolytique pour eliminer les cellules de tumeurs malignes lymphoides presentes dans des melanges de cellules

Country Status (1)

Country Link
CA (1) CA2436196A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2043662A2 (fr) * 2006-07-26 2009-04-08 Intrexon Corporation Methodes et compositions de traitement de maladie
US10260049B2 (en) 2005-08-01 2019-04-16 Virocure, Inc. Attenuated reovirus
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
US10512662B2 (en) 2016-02-25 2019-12-24 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
US10548930B2 (en) 2015-04-17 2020-02-04 Memorial Sloan Kettering Cancer Center Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
US10639366B2 (en) 2015-02-25 2020-05-05 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
US10736962B2 (en) 2016-02-25 2020-08-11 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
CN113215084A (zh) * 2021-06-11 2021-08-06 中国农业科学院兰州兽医研究所 一种羊胎儿皮肤成纤维细胞、其分离方法与应用
US11242509B2 (en) 2017-05-12 2022-02-08 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10260049B2 (en) 2005-08-01 2019-04-16 Virocure, Inc. Attenuated reovirus
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
EP2043662A4 (fr) * 2006-07-26 2010-04-14 Intrexon Corp Methodes et compositions de traitement de maladie
EP2043662A2 (fr) * 2006-07-26 2009-04-08 Intrexon Corporation Methodes et compositions de traitement de maladie
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
US10639366B2 (en) 2015-02-25 2020-05-05 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
US11426460B2 (en) 2015-02-25 2022-08-30 Memorial Sloan Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus Ankara (MVA) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
US11253560B2 (en) 2015-04-17 2022-02-22 Memorial Sloan Kettering Cancer Center Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
US10548930B2 (en) 2015-04-17 2020-02-04 Memorial Sloan Kettering Cancer Center Use of MVA or MVAΔE3L as immunotherapeutic agents against solid tumors
US10512662B2 (en) 2016-02-25 2019-12-24 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
US10765711B2 (en) 2016-02-25 2020-09-08 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human FLT3L or GM-CSF for cancer immunotherapy
US11285209B2 (en) 2016-02-25 2022-03-29 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVAΔE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
US10736962B2 (en) 2016-02-25 2020-08-11 Memorial Sloan Kettering Cancer Center Recombinant MVA or MVADELE3L expressing human FLT3L and use thereof as immuno-therapeutic agents against solid tumors
US11541087B2 (en) 2016-02-25 2023-01-03 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
US11986503B2 (en) 2016-02-25 2024-05-21 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
US11242509B2 (en) 2017-05-12 2022-02-08 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
US11884939B2 (en) 2017-05-12 2024-01-30 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
CN113215084A (zh) * 2021-06-11 2021-08-06 中国农业科学院兰州兽医研究所 一种羊胎儿皮肤成纤维细胞、其分离方法与应用

Similar Documents

Publication Publication Date Title
US7608257B2 (en) Sensitization of chemotherapeutic agent resistant neoplastic cells with a virus
US20080038822A1 (en) Virus clearance of neoplastic cells from mixed cellular compositions
US7431932B2 (en) Reovirus clearance of ras-mediated neoplastic cells from mixed cellular compositions
US20050214266A1 (en) Combination of transplantation and oncolytic virus treatment
CA2436196A1 (fr) Virus oncolytique pour eliminer les cellules de tumeurs malignes lymphoides presentes dans des melanges de cellules
CA2428805A1 (fr) Procede d'apport optimal d'un virus a une masse de tumeur solide
AU2001258077A1 (en) Clearance of neoplastic cells from mixed cellular compositions using viruses
CA2435967A1 (fr) Reovirus pour le traitement de tumeurs malignes lymphoides
TW200404099A (en) The use of ribozymes in the detection of adventitious agents
US9365823B2 (en) Virus clearance of neoplastic cells from mixed cellular compositions
TWI320056B (en) Virus clearance of neoplastic cells from mixed cellular compositions
ES2366203T3 (es) Eliminación de células neoplásicas de composiciones celulares mixtas usando virus.
CA2605803A1 (fr) Clairance virale de cellules neoplastiques de compositions cellulaires mixtes
CA2460861A1 (fr) Combinaison d'une transplantation et d'un traitement par virus oncolytique

Legal Events

Date Code Title Description
FZDE Dead